MedTrace Logo

Study of High-Dose Chemotherapy With Bone Marrow or Stem Cell Transplant for Rare Poor-Prognosis Cancers

NCT00141765 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2014-06-20

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether very high dosages of chemotherapy will improve the chance of surviving cancer.

Conditions

  • Wilms Tumor
  • Fibrosarcoma
  • Carcinoma, Round Cell
  • Nasopharyngeal Cancer
  • Brain Tumor, Recurrent

Interventions

PROCEDURE

Myeloablative Chemotherapy

High dose chemotherapy (carboplatin and thiotepa) transplant rescue

PROCEDURE

Stem Cell Rescue

autologous stem cell transplantation

Sponsors & Collaborators

  • University of Michigan Rogel Cancer Center

    lead OTHER

Principal Investigators

  • John E. Levine, MS MD · The Univeristy of Michigan

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Max Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1997-01-31
Primary Completion
2008-12-31
Completion
2010-02-28

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00141765 on ClinicalTrials.gov